NS Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

NS Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.25M	Buy	+6,216	New	+$3.18M	0.14%	93

Other funds holding VRTX

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

NS Partners's VRTX Position: Q3 2026 in Review

NS Partners opened a new position in Vertex Pharmaceuticals (VRTX) in Q3 2026: 6,216 shares worth $3.25M. The stake represents 0.14% of the portfolio and ranks #93 among its holdings.

1,556 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

NS Partners held 6,216 shares of Vertex Pharmaceuticals worth $3.25M as of Q3 2026.
Vertex Pharmaceuticals was a new NS Partners position in Q3 2026.
Vertex Pharmaceuticals made up 0.14% of NS Partners's portfolio in Q3 2026, its #93 holding.
1,556 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on NS Partners's 13F filing for Q3 2026, filed 10 Nov 2026.